What Alburex 20 Treats: Main Uses and Benefits

Therapeutic Applications and Symptom Support

The medication is commonly used to help with the restoration and maintenance of circulating blood volume where a deficiency has been demonstrated. Alburex 20 is applied in settings requiring specialized support to correct severe physiological instability.

The primary therapeutic application is relevant in contexts involving heightened systemic burden, such as conditions involving a critical lack of circulating fluid volume (hypovolemia), which may occur after severe blood loss due to major trauma or surgical hemorrhage. It is a supportive measure for acute, life-threatening episodes of hypovolemic shock.

The medication is also relevant for managing certain symptomatic presentations in systemic illnesses marked by severe protein depletion (hypoalbuminemia). This includes fluid management in conditions like advanced liver cirrhosis (for volume support after large fluid removal) or during septic shock where significant volume expansion is necessary. The use of the 20% solution is relevant when supportive symptom management is appropriate for complex fluid shifts and acute volume deficits, assisting with managing symptomatic discomfort related to edema. The main benefit is providing support that helps ease the overall symptom burden associated with acute physiological strain.

---

Quick Fact: Volume Stability

Property	Description
Conditions Characterized by Acute Need	Acute circulatory volume deficiency
Core Symptom Managed	Symptoms related to systemic imbalance (e.g., hemodynamic instability)
Common Clinical Contexts	Hypovolemic shock, extensive burns, severe sepsis
Supports Functional Stability	Supports the restoration and maintenance of circulating volume

Who Can and Cannot Use Alburex 20?

This section outlines the official eligibility and non-eligibility information for Alburex 20 based on government regulatory documents.

---

Absolute Non-Eligibility (Contraindications)

Alburex 20 must not be used in the following populations:

• Patients with known hypersensitivity (allergy) to human albumin or to any of the other excipients contained in the product.
• Patients experiencing severe anaemia or cardiac failure when these conditions are combined with a normal or increased circulating blood volume (intravascular volume).

---

Conditional or Restricted Use

Use of Alburex 20 requires special caution and monitoring in conditions where an abnormal increase in blood volume (hypervolaemia) or blood thinning (haemodilution) could pose a significant risk to the patient. These conditions include:

• Decompensated cardiac insufficiency
• High blood pressure (hypertension)
• Oesophageal varices
• Pulmonary oedema
• Haemorrhagic diathesis (bleeding predisposition)

---

Special Population Status

Population	Regulatory Status
Paediatrics (Children)	Safety and effectiveness not established in clinical trials. Use is based on clinical experience.
Pregnancy/Lactation	Safety not established in controlled trials. Use is conditional on the treating physician determining that the benefits outweigh the risks.

Interactions with other medicines and products

The official regulatory profile for Alburex 20 is defined primarily by restrictions on its co-administration and mixing, rather than by systemic drug-drug interactions. Government regulatory documents explicitly state that no specific systemic interactions of Human Albumin 20% with other medicinal products are known, meaning no specific enzyme-mediated or pharmacokinetic interactions are documented in the official labeling. The focus is instead on strict rules concerning administration incompatibilities to ensure patient safety.

Administration Restrictions (Incompatibilities)

Specific prohibitions must be observed for the safe infusion of Alburex 20. These requirements are formal constraints documented in the medicine’s official regulatory labeling:

• Prohibited Co-administration: The medicine must not be combined or mixed with certain biological components or nutritional solutions in the same intravenous line. This includes whole blood and packed red cells. The product must also not be mixed with protein hydrolysates or amino acid solutions.
• Prohibited Diluent: It is strictly documented that Alburex 20 must not be diluted with water for injections. This specific type of co-administration is officially recognized to carry a risk of resulting in haemolysis (red blood cell destruction) in the recipient.
• Mandated Diluents: The solution may only be diluted using specified isotonic solutions, such as 0.9% sodium chloride or 5% glucose solution, as per regulatory instruction.

These constraints constitute the full documented interaction profile, defining the necessary procedural rules for safe use.

Alburex 20 delivers Human Albumin into the systemic circulation via intravenous infusion. Its primary biological target is the intravascular space, where it acts as a colloid to stabilize the circulating volume. The 200 g/L solution is hyperoncotic relative to native plasma, establishing a substantial colloid osmotic pressure (COP) gradient across the capillary endothelium.

This high COP provides an osmotic drag force that facilitates the movement of interstitial fluid back into the plasma compartment. This process directly modulates the Starling forces governing capillary fluid exchange, resulting in a net intravascular volume expansion that can be up to approximately four times the volume infused. At a molecular level, albumin functions as a non-specific carrier protein, reversibly binding to and transporting various endogenous and exogenous substances, including hormones, fatty acids, bilirubin, and certain medicinal products. This binding and transport capacity occurs through non-covalent hydrophobic and electrostatic interactions at specific sites on the albumin molecule, modulating the systemic distribution and free concentration of these molecules.

How Alburex 20 is Used: Principles of Administration

Alburex 20 is a specialized Human Albumin product supplied as a 20% solution for intravenous infusion only. The primary principle governing its use is that the dose must be highly individualized and is determined by monitoring the patient's circulating blood volume and clinical response, not solely by measuring plasma albumin levels.

---

Administration and Preparation Requirements

This high-concentration solution must be administered intravenously in a clinical setting where patient monitoring can occur. The infusion rate is carefully adjusted to the patient’s specific needs and circulatory status. For instance, in the absence of shock, a slower rate of 1 to 2 mL per minute is generally indicated. If large volumes are to be administered, the solution should be warmed to room or body temperature prior to infusion. The product can be diluted in isotonic solutions, such as 5% glucose or 0.9% sodium chloride, but must not be diluted with sterile water for injection due to the risk of hemolysis. Once opened, the vial's contents must be used immediately, and any unused portion must be discarded, as the solution contains no antimicrobial preservatives.

---

Official Dosing Patterns

While the exact dose is variable, initial dosing patterns are utilized for guidance:

Clinical Context	Official Dosage Guidance
Acute Volume Loss	Initial dose is typically 20 g to 25 g of Human Albumin.
Paracentesis	8 g for every 1,000 mL of ascitic fluid removed.

The maximum daily dose should not exceed 2 g of albumin per kg of body weight. For specific populations, such as pediatric patients, the dosage must be adjusted to their individual requirements.

Research Evidence / Overview of Studies for Alburex 20

Alburex 20 has been the subject of several types of clinical investigation, primarily Randomized Controlled Trials (RCTs) and comprehensive systematic reviews that combine findings from multiple studies. Research focuses on how the medicine, a plasma protein solution, is used in critical care and to manage specific conditions involving systemic imbalance.

---

Evidence for Volume Restoration in Circulatory Shock

Research has explored the use of Alburex 20 for individuals experiencing acute loss of circulating blood volume, such as after severe trauma or major surgery, in conditions commonly referred to as hypovolemia or shock. The primary studies conducted were short-term randomized trials that compared the solution to other standard fluids used for immediate volume support. These studies focused on measuring changes in mean arterial pressure and survival rates over the short-term (typically 28 days).

Findings from these trials describe patterns where the solution was observed to be associated with short-term changes in measured hemodynamic markers. Long-term outcomes and functional recovery beyond 28 days are not extensively characterized, and results apply only to the specific, critically ill populations studied.

---

Evidence as a Treatment Adjunct in Severe Sepsis and Septic Shock

The most extensive research, including large-scale, multicenter RCTs, has been conducted in critically ill adults with severe sepsis or septic shock. These studies explored whether administering the solution, alongside standard care, changed patient outcomes (such as survival and organ function). Studies evaluating key clinical markers such as all-cause survival at 28 and 90 days, as well as changes in organ function scores, were monitored.

Evidence regarding survival patterns remains mixed when pooling data across all trials, particularly for patients with sepsis who are not in the state of shock. Therefore, certainty remains low for the broad sepsis population. The specific patient criteria for whom administration is studied remain under investigation.

---

Evidence for Managing Complications of Chronic Liver Disease

The solution was evaluated in individuals with advanced liver cirrhosis who undergo large-volume fluid removal (paracentesis). The research explored short-term outcomes related to systemic or functional imbalance that can follow this procedure. Multiple RCTs consistently described patterns where post-paracentesis complications, such as circulatory dysfunction and renal impairment, differed when the solution was used. Despite these findings, the impact of using the solution on long-term patient survival remains a topic of specialized research.

Key Studies & References Albumin replacement in patients with severe sepsis or septic shock (The ALBIOS trial)

Common questions about Alburex 20 (FAQ)

---

Q: Can Alburex 20 be given to children, and what is the typical dose?

Regulatory documents indicate that Alburex 20 can be administered to the paediatric population. The dose, however, must be highly individualized and adjusted according to the child’s body weight, the seriousness of their condition, and any ongoing fluid loss. Official labeling indicates that the maximum total daily amount for guidance is 2 grams of albumin per kilogram of body weight.

---

Q: What are the official clinical conditions that Alburex 20 is used to treat?

Official product information states that Alburex 20 is indicated for the restoration and maintenance of circulating blood volume when a patient has a medically documented volume deficiency and requires a colloid solution. This can include specific clinical scenarios such as hypovolemia (low blood volume), circulatory shock, and certain complications that may follow procedures like large-volume paracentesis.

---

Q: How is Alburex 20 different from Alburex 5?

Alburex 20 is supplied as a 20% concentration solution. This concentration is hyperoncotic, meaning it generates an osmotic pressure about four times greater than normal blood plasma. This high pressure helps facilitate the movement of fluid from the surrounding body tissues back into the blood vessels for volume support. In comparison, a 5% albumin solution is osmotically equivalent to normal plasma.

---

Q: How long does the volume expansion effect of Alburex 20 last in the body?

The Human Albumin protein has an average biological half-life of approximately 19 days in healthy individuals. The immediate volume expansion effect in patients, which is its primary clinical purpose, can vary based on the patient’s overall condition. Official information suggests this clinical volume support may last for a period of some hours.

---

Q: How quickly does Alburex 20 start working after infusion?

Given its use as an intravenous volume expander, the onset of the volume expansion effect occurs shortly after administration. Clinical data shows that in healthy subjects, the majority of the infused albumin (over 90%) remains within the blood vessels for at least the first two hours.

---

Q: Can Alburex 20 be administered via an intramuscular or subcutaneous injection instead of IV?

No. Regulatory documents specify that this product is strictly limited to intravenous infusion. Administration through other routes, such as intramuscular (into a muscle) or subcutaneous (under the skin) injection, is not supported by the official labeling.

---

Q: Is it true that Alburex 20 can carry and transport other medicines in the body?

Yes, this is an inherent function of the albumin protein. Official documents state that Human Albumin acts as a natural carrier protein in the blood. It can bind to and transport various substances, including hormones, enzymes, toxins, and other medicinal products, alongside its primary role in stabilizing blood volume.

How to Store and Dispose of Alburex 20

The official labeling for Alburex 20 (Human Albumin) mandates specific environmental and handling conditions to maintain its stability.

---

Storage Requirements

Condition	Requirement
Temperature	Store at a temperature not exceeding 25 °C or 30 °C (regional variations apply), and do not freeze the solution.
Protection	Keep the container in the original outer carton to protect from light.
Child Safety	The medicine must be kept out of the sight and reach of children.
Stability	Use the solution immediately upon opening, or within four hours. Discard any unused portion remaining, as the product contains no antimicrobial preservatives.

---

Disposal Instructions

Unused or expired Alburex 20 must be disposed of in accordance with local pharmaceutical waste regulations. Do not throw the medicine away using wastewater or typical household waste; instead, consult a pharmacist for guidance on proper disposal.